NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals
NHS England
This tender has closed
The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.
Key details
Procurement
- 33600000 Pharmaceutical products
What happened
NHS England awarded this contract to Mercury Pharmaceuticals Limited | Gerot Lannach UK Ltd | Bayer Plc | Aventis Pharma ltd t/a Sanofi | Tillomed Laboratories ltd | Sandoz Ltd | Pfizer Ltd | Accord-UK Ltd | Otsuka Pharmaceuticals UK Limited | Morningside Pharmaeuticals | Astellas Pharma Ltd | Wockhardt UK Limited | Lupin Healthcare (UK) Limited | Ipsen | Mylan | Neuraxpharm UK Ltd | Ridge Pharma | Ferring Pharmaceuticals Ltd | Drugsrus Ltd | medac Pharma LLP | Kent Pharma Ltd | Martindale Pharma | Janssen-Cilag Ltd | Day Lewis Medical Ltd | Zentiva Pharma UK Ltd | Teva UK Limited | Glenmark Pharmaceuticals Europe Limited | Pharmasure | Xiromed | Recordati Rare Diseases UK Ltd | Aspire Pharma Limited | Chiesi Limited | Selective Supplies Ltd. | Napp Pharmaceuticals Ltd | Aspen Pharmacare UK Limited | Gedeon Richter UK Ltd | Nordic Pharma | Novartis Pharmaceuticals UK Ltd | Synchrony | Norgine Pharmaceuticals Limited | Orifarm UK | QDEM PHARMACEUTICALS LIMITED | Eli Lilly & Company Ltd | CST Pharma Limited | ROVI Biotech Ltd | Merck Serono Limited | Takeda UK Ltd | Tetris Pharma Lts | Dexcel Pharma Ltd | Theramex HQ UK worth £304,504,000 on 24 Apr 2023. The contract runs until 30 Apr 2025.
Description
NHS Framework Agreement for Branded Medicines - National Proprietary Pharmaceuticals
Offer reference number: CM/PHR/22/5675
CM/PHR/22/5675/01 - NHS Framework Agreement for Branded Medicines - National Category Tender Lot 1. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
CM/PHR/22/5675/02 - NHS Framework Agreement for Branded Medicines - National Tender Lot 2. Period of framework: 1 May 2023 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
Awarded suppliers (50)
- Mercury Pharmaceuticals Limited
- Gerot Lannach UK Ltd
- Bayer Plc
- Aventis Pharma ltd t/a Sanofi
- Tillomed Laboratories ltd
- Sandoz Ltd
- Pfizer Ltd
- Accord-UK Ltd
- Otsuka Pharmaceuticals UK Limited
- Morningside Pharmaeuticals
- Astellas Pharma Ltd
- Wockhardt UK Limited
- Lupin Healthcare (UK) Limited
- Ipsen
- Mylan
- Neuraxpharm UK Ltd
- Ridge Pharma
- Ferring Pharmaceuticals Ltd
- Drugsrus Ltd
- medac Pharma LLP
- Kent Pharma Ltd
- Martindale Pharma
- Janssen-Cilag Ltd
- Day Lewis Medical Ltd
- Zentiva Pharma UK Ltd
- Teva UK Limited
- Glenmark Pharmaceuticals Europe Limited
- Pharmasure
- Xiromed
- Recordati Rare Diseases UK Ltd
- Aspire Pharma Limited
- Chiesi Limited
- Selective Supplies Ltd.
- Napp Pharmaceuticals Ltd
- Aspen Pharmacare UK Limited
- Gedeon Richter UK Ltd
- Nordic Pharma
- Novartis Pharmaceuticals UK Ltd
- Synchrony
- Norgine Pharmaceuticals Limited
- Orifarm UK
- QDEM PHARMACEUTICALS LIMITED
- Eli Lilly & Company Ltd
- CST Pharma Limited
- ROVI Biotech Ltd
- Merck Serono Limited
- Takeda UK Ltd
- Tetris Pharma Lts
- Dexcel Pharma Ltd
- Theramex HQ UK
Contact
Identifiers
Explore related tenders
Other tenders from NHS England
View all →External ID: cf-ocds-b5fd17-f3419ee6-884e-4ba4-9f88-cdfcb350ba4e • Added 4 October 2026